Literature DB >> 33322215

Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immunofluorescence Study.

Arnulf Mayer1, Maximilian Haist1,2, Carmen Loquai2, Stephan Grabbe2, Matthias Rapp1, Wilfried Roth3, Peter Vaupel1, Heinz Schmidberger1.   

Abstract

Following the introduction of immune checkpoint inhibitors, a substantial prolongation of the overall survival has been achieved for many patients with multiple brain metastases from melanoma. However, heterogeneity between individual tumor responses is incompletely understood. In order to determine the impact of the individual tumor phenotype on the prognosis of melanoma patients, we examined surgical sections from 33 patients who were treated with radiotherapy (whole-brain radiotherapy, WBRT, stereotactic radiotherapy, STX, or both) and Ipilimumab. We analyzed multiplex staining of the hypoxia marker GLUT-1, the adenosine (ADO)-associated enzymes CD73 and CD39, and CD8, a marker of cytotoxic T lymphocytes (CTL) on a single-cell basis using QuPath. Additionally, the MOSAIC interaction analysis algorithm was used to explore the hypothesis that CTL systematically avoid GLUT-1high tumor areas. Our results revealed, that a strong GLUT-1 expression, low numbers of CTL, or exclusion of CTL from the tumor were correlated with significant prognostic detriment. Hypoxic tumors overall have smaller amounts of CTL, and spatial analysis revealed a repellent effect of hypoxia on CTL. In contrast to in vitro studies, specific upregulation of ADO-related enzymes CD73 and CD39 in GLUT-1high tumor regions was never observed. In this study, we could show direct in vivo evidence for hypoxia-mediated immunosuppression in melanoma. Moreover, this study suggests a significant prognostic relevance of the tumor immune phenotype, the strength of CD8 infiltration in the tumor, and the expression of hypoxia marker GLUT-1 on melanoma cells. Last, our results suggest a temporal stability of the microenvironment-mediated immunosuppressive phenotype in melanoma.

Entities:  

Keywords:  adenosine; hypoxia; immune checkpoint inhibitor; immunosuppression; ipilimumab; multiplex immunohistochemistry; radiotherapy; spatial statistics; tumor microenvironment

Year:  2020        PMID: 33322215      PMCID: PMC7763902          DOI: 10.3390/cancers12123753

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  58 in total

Review 1.  Hypoxia in cancer: significance and impact on clinical outcome.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

2.  Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.

Authors:  Cristina Maccalli; Diana Giannarelli; Filippo Capocefalo; Lorenzo Pilla; Ester Fonsatti; Anna Maria Di Giacomo; Giorgio Parmiani; Michele Maio
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

Review 3.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

4.  Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia.

Authors:  Kristin Synnestvedt; Glenn T Furuta; Katrina M Comerford; Nancy Louis; Jorn Karhausen; Holger K Eltzschig; Karl R Hansen; Linda F Thompson; Sean P Colgan
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

5.  Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia.

Authors:  H Lyng; K Sundfør; E K Rofstad
Journal:  Radiother Oncol       Date:  1997-08       Impact factor: 6.280

Review 6.  Immunosuppressive activities of adenosine in cancer.

Authors:  Bertrand Allard; Paul A Beavis; Phillip K Darcy; John Stagg
Journal:  Curr Opin Pharmacol       Date:  2016-05-19       Impact factor: 5.547

Review 7.  Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy.

Authors:  Yiliang Li; Sapna Pradyuman Patel; Jason Roszik; Yong Qin
Journal:  Front Immunol       Date:  2018-07-16       Impact factor: 7.561

8.  CD73 expression and clinical significance in human metastatic melanoma.

Authors:  Inês Monteiro; Selena Vigano; Mohamed Faouzi; Isabelle Treilleux; Olivier Michielin; Christine Ménétrier-Caux; Christophe Caux; Pedro Romero; Laurence de Leval
Journal:  Oncotarget       Date:  2018-06-01

Review 9.  Therapeutic potential of adenosine kinase inhibition-Revisited.

Authors:  Michael F Jarvis
Journal:  Pharmacol Res Perspect       Date:  2019-07-22

10.  Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts.

Authors:  Jon-Vidar Gaustad; Trude G Simonsen; Marit N Leinaas; Einar K Rofstad
Journal:  BMC Cancer       Date:  2012-09-04       Impact factor: 4.430

View more
  4 in total

Review 1.  Oxygen and metabolic reprogramming in the tumor microenvironment influences metastasis homing.

Authors:  Vinod S Bisht; Kuldeep Giri; Deepak Kumar; Kiran Ambatipudi
Journal:  Cancer Biol Ther       Date:  2021-10-25       Impact factor: 4.742

Review 2.  CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors.

Authors:  Vicky Mengfei Qin; Nicole M Haynes; Criselle D'Souza; Paul J Neeson; Joe Jiang Zhu
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

Review 3.  CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer-Clinical Perspectives.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 8.786

4.  β2 Integrins on Dendritic Cells Modulate Cytokine Signaling and Inflammation-Associated Gene Expression, and Are Required for Induction of Autoimmune Encephalomyelitis.

Authors:  Monika Bednarczyk; Vanessa Bolduan; Maximilian Haist; Henner Stege; Christoph Hieber; Lisa Johann; Carsten Schelmbauer; Michaela Blanfeld; Khalad Karram; Jenny Schunke; Tanja Klaus; Ingrid Tubbe; Evelyn Montermann; Nadine Röhrig; Maike Hartmann; Jana Schlosser; Tobias Bopp; Björn E Clausen; Ari Waisman; Matthias Bros; Stephan Grabbe
Journal:  Cells       Date:  2022-07-13       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.